Surmodics, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000BZ2QG2
SRDX
Surmodics, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Medical Devices
NAME
Surmodics, Inc.
ISIN
US8688731004
TICKER
SRDX
MIC
XNAS
REUTERS
SRDX.OQ
BLOOMBERG
SRDX US
F&G:
77
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mi., 30.04.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025.
Second Quarter Fiscal 2025 Financial Summary
Tota...
Surmodics
Di., 29.04.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30.
Given the pending acquisition by GTCR, Surmodics will not be hosting a liv...
Surmodics
Di., 22.04.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy i...
Surmodics
Do., 03.04.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral ar...
Surmodics
Fr., 07.03.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission’s (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated ...
Surmodics
Mo., 03.02.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is...
Surmodics
Do., 30.01.2025
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024.
First Quarter Fiscal 2025 Financial Summary
Total Revenue of $29.9 million, a decrease of 2% year-over-year
Total Revenue exclu...
Surmodics
Mi., 06.11.2024
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024.
Fourth Quarter Fiscal 2024 Financial Summary
Total Revenue of $33.2 million, an increase of 19% year-over-year
T...
Surmodics
Mi., 30.10.2024
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium ...
Surmodics
Di., 01.10.2024
Surmodics
US8688731004
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System.
The Pounce XL Thrombectomy System is indicated for the non-surgical removal of thrombi and emboli from the perip...
Surmodics
Informationen zu Product Placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
